Christopher Buxton

I'll research this attorney before drafting.

Christopher Buxton — Kirkland & Ellis (Dallas) — analyst summary

Specialty / focus. Buxton's practice is IP litigation with an emphasis on patent and trade secret matters in the U.S. district courts and the PTAB. His firm bio describes work across pharmaceuticals, medical devices, telecommunications and optical networks, video recording, FPGAs, semiconductors, and digital rights management — a fairly broad electronics-plus-life-sciences mix consistent with his undergraduate biomedical engineering degree. The named tracked case, XiFi Networks R&D, Inc. v. Samsung Electronics Co., Ltd. (E.D. Tex. No. 2:24-cv-01057-JRG), is squarely in the wireless-standards lane: XiFi asserts patents against Samsung products implementing IEEE 802.11be Multi-Link Operation (MLO) — smartphones, TVs, laptops, tablets, and wearables — and Samsung responded with a large parallel PTAB campaign (multiple IPRs plus PGR2025-00067/68/69). Attribution of those PTAB filings to Buxton specifically is not confirmed in the public record I reviewed; Samsung's papers list other counsel of record.

Side preference. He is a defense-side practitioner. All three tracked appearances are on the defendant side, with no plaintiff-side appearances in the tracked data. The XiFi v. Samsung matter is a defense of an operating company against a standards-focused NPE, and his PTAB work for petitioners in the pharmaceutical space (Hope Medical) shows he is comfortable on the challenging side of validity proceedings. Nothing in the record indicates plaintiff/NPE-side prosecution of patent claims.

Firm context. Currently an associate in Kirkland & Ellis's Dallas office (per the firm's lawyer bio), admitted in Texas in 2019 and registered before the USPTO (Reg. No. 75,436); admitted to the Eastern, Northern, and Western Districts of Texas. His prior firm was Jones Day (Dallas), where he was counsel of record in multiple PTAB matters through 2024 — including as back-up counsel on a 2024 IPR petition — and he is still listed as Jones Day in some USPTO-derived directories, which lag. The specific Jones Day-to-Kirkland transition date (reported by a third-party data aggregator as late 2024) is not independently confirmed by a primary source and should be treated as approximate. The tracked-case data labels one appearance "Counsel," but the firm site currently lists him as an associate.

Notable matters and PTAB/IPR experience. The prominent tracked case is the Samsung Wi-Fi/MLO defense noted above; two other tracked defendant-side appearances are unnamed in the underlying data. On the PTAB side, he was petitioner's counsel in Hope Medical Enterprises, Inc. v. Fennec Pharmaceuticals, Inc., IPR2022-00125 (U.S. Patent No. 10,792,363, anhydrous sodium thiosulfate), where he was accepted into the Board's LEAP program and argued at the March 21, 2023 oral hearing with additional allotted time. The result was adverse to his client: the Board's September 1, 2023 final written decision granted Fennec's revised noncontingent motion to amend and held the substitute claims not shown unpatentable — a rare successful motion-to-amend outcome. He also co-authored a January 2025 World Intellectual Property Review article on patent damages developments in Brumfield v. IBG and EcoFactor v. Google.

Bar / education. J.D. with honors, University of Texas at Austin School of Law (2019; Articles Editor, Texas Law Review and Texas Intellectual Property Law Journal); B.S.E. in biomedical engineering, Duke University (2015). Texas bar, 2019; USPTO registered. Member, Hon. Barbara M.G. Lynn American Inn of Court, 2024–2025.

Note on sourcing: firm bio and PTAB filings are primary/authoritative; the Jones Day tenure and transition timing come from PTAB dockets and an aggregator profile, and should be verified with the attorney before use in a filing or client communication.